Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06634420 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 13 words
    • Site details revised at 2 of 29 sites
    • Publications: details revised at 1 of 1 entry
  2. Re-verified, no change to tracked fieldsv18
  3. Enrollment target: estimated 60 to confirmed 80
    • Primary completion date changed from estimate of Apr 2026 to Feb 10, 2026
    v17
  4. Study sites: 30 to 29v16
  5. Study sites: 31 to 30v15
Show 13 earlier versionsHide 13 earlier versions
  1. Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 30 to 31
    v14
  2. Study sites: 29 to 30v13
  3. Study sites: 27 to 29v12
  4. Study sites: 16 to 27v11
  5. Study sites: 14 to 16v10
  6. Eligibility criteria expanded, about 17 wordsv9
  7. Study sites: 13 to 14v8
  8. Study sites: 8 to 13v7
  9. Study sites: 6 to 8v6
  10. Study sites: 3 to 6
    • Start date changed from estimate of Dec 2024 to Jan 15, 2025
    v5
  11. Start date: Oct 2024 to Dec 2024
    • Study sites: 1 to 3
    v4
  12. Secondary endpoints: 9 to 14v3
  13. Study title expanded, about 1 wordv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This Phase 3 study aims to evaluate the efficacy and safety of NTLA-2002 compared to placebo in participants with HAE.
Trial Details
NCT Number NCT06634420
Lead Sponsor Intellia Therapeutics
Conditions
(from sponsor)		 Hereditary Angioedema
Related terms Angioedemas, Hereditary
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov